3:23 PM
 | 
Nov 10, 2017
 |  BioCentury  |  Finance

Building Quan

How Quan plans to deploy its inaugural $150M healthcare fund

A trio of Chinese biopharma veterans is taking advantage of a growing domestic biotech industry and a wave of innovation-friendly regulatory and policy reforms to establish Quan Capital Management LLC, a global VC that could help healthcare companies on both sides of the Pacific navigate the China market.

Its inaugural fund, Quan Venture Fund L.P., closed at about $150 million in August and will invest in 10 to 15 companies.

While the focus will be on novel therapeutics, the fund will also invest in related areas such as enabling technologies and companion diagnostics.

Together Quan’s three managing directors -- Samantha Du, Marietta Wu and Stella Xu -- have experience in venture investing, company building and operations and BD.

“All the managing directors, previously on the investment side and/or on the operation side, were deeply involved with the overall growth of the industry,” said Wu.

Du and Wu co-founded Shanghai biotech Zai Lab Ltd. in 2013. The cancer, autoimmune and infectious disease company raised $172.5 million in a bumped-up IPO on NASDAQ in September.

Du is Zai’s chairman and CEO, and previously served as managing director of healthcare investments at Sequoia Capital China. Prior to joining Sequoia, Du was founder and CEO of Hutchison MediPharma Ltd., one of China’s first innovator biotechs and a subsidiary of Hutchison China MediTech Ltd., of...

Read the full 1099 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >